If you missed us at ASBrS 2021…

We welcome you to watch a recording of a live industry symposium at ASBrS: Drs. Boolbol and Russell discuss the utility of neoadjuvant endocrine therapy to de-escalate surgery in HR-positive, HER2-negative breast cancer patients and how the Oncotype DX Breast Recurrence Score® test can predict response to neoadjuvant endocrine therapy.1

De-escalating Breast Cancer Surgery with Neoadjuvant Endocrine Therapy


Susan K. Boolbol, MD, FACS
System Chief, Breast Surgical Oncology and Breast Program
Nuvance Health

Christy Russell, MD
Senior Director, Global Medical Affairs
Exact Sciences/Genomic Health


    1. Iwata H, et al. Breast Cancer Res Treat. 2019.

Making cancer care smarter.™

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.